Filing Flows › United Therapeutics (UTHR) › Gross margin
United Therapeutics (UTHR) gross margin by quarter
United Therapeutics' gross margin was 88.1% in Q3 2026 (third quarter 2026), +0.8 pts from Q2 2026. Over the last 7 quarters it ranged from 82.9% (Q1 2026) to 89.0% (Q2 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 88.1% | +0.8 pts | +0.7 pts |
| Q2 2026 | 87.3% | +4.4 pts | -1.7 pts |
| Q1 2026 | 82.9% | -4.0 pts | -5.4 pts |
| Q4 2025 | 86.9% | -0.5 pts | — |
| Q3 2025 | 87.4% | -1.7 pts | — |
| Q2 2025 | 89.0% | +0.7 pts | — |
| Q1 2025 | 88.4% | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' gross margin?
United Therapeutics' gross margin was 88.1% in Q3 2026 (third quarter 2026), +0.8 pts from Q2 2026.
How has United Therapeutics' gross margin changed?
Over the last 7 quarters it ranged from 82.9% (Q1 2026) to 89.0% (Q2 2025).